Search research articles
Contact Us
Filters
Showing results (51-60 of 183) with videos related to
Page
of 19
Sort By:
The Journal of Urology
|
September 5, 2025
Editorial Comment
Gregory Hemenway, Elizabeth R Plimack, Daniel M Geynisman
European Urology
|
August 25, 2014
Corticosteroids and prostate cancer: friend or foe?
Daniel M Geynisman, Russell Z Szmulewitz, Elizabeth R Plimack
European Urology
|
March 8, 2016
Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4
Tim N Beck, Erica A Golemis, Daniel M Geynisman
European Urology
|
June 28, 2015
Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
Daniel M Geynisman, Eric A Ross, Elizabeth R Plimack
European Urology
|
September 4, 2012
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer
Daniel M Geynisman, Russell Z Szmulewitz, Walter M Stadler
Therapeutic Advances in Medical Oncology
|
August 8, 2018
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Therapeutic Advances in Medical Oncology
|
August 2, 2023
Role of perioperative immunotherapy in localized renal cell carcinoma
Jasmeet Kaur, Goutham Patil, Daniel M Geynisman, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
August 30, 2020
Liquefaction and Rupture of Angiomyolipoma after Embolization
Robert N Uzzo, John Drevik, Joseph Panaro, et al.
Current Opinion in Urology
|
July 20, 2022
The past, present, and future of pT0 in bladder cancer clinical trials
Jared P Schober, Elizabeth Plimack, Daniel M Geynisman, et al.
European Urology Focus
|
May 20, 2019
First-line Immunotherapy in Metastatic Urothelial Carcinoma
Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Page
of 19
Search research articles
Search
Showing results (51-60 of 183) with videos related to
Sort By:
Page
of 19
The Journal of Urology
|
September 5, 2025
Editorial Comment
Gregory Hemenway, Elizabeth R Plimack, Daniel M Geynisman
European Urology
|
August 25, 2014
Corticosteroids and prostate cancer: friend or foe?
Daniel M Geynisman, Russell Z Szmulewitz, Elizabeth R Plimack
European Urology
|
March 8, 2016
Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4
Tim N Beck, Erica A Golemis, Daniel M Geynisman
European Urology
|
June 28, 2015
Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
Daniel M Geynisman, Eric A Ross, Elizabeth R Plimack
European Urology
|
September 4, 2012
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer
Daniel M Geynisman, Russell Z Szmulewitz, Walter M Stadler
Therapeutic Advances in Medical Oncology
|
August 8, 2018
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Therapeutic Advances in Medical Oncology
|
August 2, 2023
Role of perioperative immunotherapy in localized renal cell carcinoma
Jasmeet Kaur, Goutham Patil, Daniel M Geynisman, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
August 30, 2020
Liquefaction and Rupture of Angiomyolipoma after Embolization
Robert N Uzzo, John Drevik, Joseph Panaro, et al.
Current Opinion in Urology
|
July 20, 2022
The past, present, and future of pT0 in bladder cancer clinical trials
Jared P Schober, Elizabeth Plimack, Daniel M Geynisman, et al.
European Urology Focus
|
May 20, 2019
First-line Immunotherapy in Metastatic Urothelial Carcinoma
Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Page
of 19